Assignee
ADC THERAPEUTICS SA
CH·14 granted patents·28 pending applications·26 citations·filing 2015–2024
Top patents by PatentIndex Score
42 records- 0190US10780096B2Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2015·Granted Sep 22, 2020·7 cites·35 claims
- 0287US10544223B2Combination therapy with an anti-axl antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Granted Jan 28, 2020·5 cites·21 claims
- 0386US11160872B2Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2018·Granted Nov 2, 2021·2 cites·24 claims
- 0485US11938192B2Dosage regimes for the administration of an anti-CD19 ADCADC THERAPEUTICS SA·Filed 2022·Granted Mar 26, 2024·1 cites·19 claims
- 0585US11318211B2Dosage regimes for the administration of an anti-CD19 ADCADC THERAPEUTICS SA·Filed 2018·Granted May 3, 2022·4 cites·16 claims
- 0684US9828426B2Antibodies against kidney associated antigen 1 and antigen binding fragments thereofADC THERAPEUTICS SA·Filed 2016·Granted Nov 28, 2017·3 cites·21 claims
- 0782US11596696B2Combination therapy with an anti-CD25 antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Granted Mar 7, 2023·3 cites·13 claims
- 0878US11426467B2Dosage regimes for the administration of an anti-CD25 ADCADC THERAPEUTICS SA·Filed 2018·Granted Aug 30, 2022·1 cites·25 claims
- 0974US2021054067A1Antibodies against kidney associated antigen 1 and antigen binding fragments thereofADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 1070US2024269314A1Pyrrolobenzodiazepine-antibody conjugates and uses thereofADC THERAPEUTICS SA·Filed 2024·Application pending·0 cites
- 1169US2023053603A1Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 1268US2023106885A1Dosage regimeADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 1367US11813335B2Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2021·Granted Nov 14, 2023·0 cites·17 claims
- 1466US2021113587A1Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2020·Application pending·0 cites
- 1566US2023149556A1Combination therapyADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 1665US11484606B2Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2021·Granted Nov 1, 2022·0 cites·17 claims
- 1765US2023039868A1Dosage regimesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 1863US11976122B2Anti-IL13Rα2 antibodiesADC THERAPEUTICS SA·Filed 2021·Granted May 7, 2024·0 cites·13 claims
- 1963US2023201366A1Anti-psma conjugatesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 2063US2023285580A1Anti-il-13ralpha2 conjugatesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 2162US11084872B2Method for treating breast cancerADC THERAPEUTICS SA·Filed 2018·Granted Aug 10, 2021·0 cites·23 claims
- 2262US10597450B2Antibodies against kidney associated antigen 1 and antigen binding fragments thereofADC THERAPEUTICS SA·Filed 2017·Granted Mar 24, 2020·0 cites·70 claims
- 2362US2025163488A1Conjugation method involving a transglutaminase at the fc region comprising a trimmed n-glycanADC THERAPEUTICS SA·Filed 2023·Application pending·0 cites
- 2461US11384098B2Pyrrolobenzodiazepine-antibody conjugatesADC THERAPEUTICS SA·Filed 2018·Granted Jul 12, 2022·0 cites·25 claims
- 2561US2022096654A1Pyrrolobenzodiazepine-antibody conjugates and uses thereofADC THERAPEUTICS SA·Filed 2021·Application pending·0 cites
- 2660US2025186604A1Anti-psma antibody conjugatesADC THERAPEUTICS SA·Filed 2024·Application pending·0 cites
- 2760US2025121084A1Anti-claudin-6 conjugatesADC THERAPEUTICS SA·Filed 2024·Application pending·0 cites
- 2859US2018346563A1Polynucleotides and polypeptide sequences involved in cancerADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
- 2957US2025352658A1Combination therapy using antibody-drug conjugatesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 3056US2025381282A1Composition comprising a pyrrolobenzodiazepine-based antibody drug conjugateADC THERAPEUTICS SA·Filed 2023·Application pending·0 cites
- 3155US2020405879A1Combination therapyADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
- 3255US2018369269A1Antibodies that specifically block the biological activity of a tumor antigenADC THERAPEUTICS SA·Filed 2017·Application pending·0 cites
- 3353US2022347309A1Pyrrolobenzodiazepine resistanceADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 3450US2020129637A1Combination therapy with an anti-axl antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
- 3550US2022111065A1Molecular adjuvantADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 3649US2023099010A1Combination therapyADC THERAPEUTICS SA·Filed 2020·Application pending·0 cites
- 3749US2023132256A1Combination therapyADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 3847US2021322564A1Combination therapyADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 3945US2022305132A1Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agentADC THERAPEUTICS SA·Filed 2020·Application pending·0 cites
- 4043US2025170258A1Dosage regimenADC THERAPEUTICS SA·Filed 2023·Application pending·0 cites
- 4141US2022175948A1Treatment of car t-cell toxicityADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 4240US2020129638A1Combination therapy with an anti-psma antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →